Axcan Pharma to Hold Special Meeting of Shareholders on January 25, 2008
January 22 2008 - 1:00PM
Marketwired
MONT-SAINT-HILAIRE, QUEBEC (TSX: AXP)(NASDAQ: AXCA) will hold a
special meeting of shareholders, at which shareholders will be
asked to consider the previously-announced proposed arrangement
with an affiliate of TPG Capital.
The special meeting will be held on Friday, January 25, 2008, at
9:30 a.m. in Montreal at the Hotel Omni Mont-Royal, 1050 Sherbrooke
Street West, Montreal, Quebec, H3A 2R6, in the Salle Printemps. For
those who are unable to attend in person, a video webcast of the
special meeting will be available live on the Company's website at
www.axcan.com. An archive of the video webcast will also be
available on the Company's website approximately one hour after the
end of the special meeting.
ABOUT AXCAN PHARMA
Axcan is a leading multinational specialty pharmaceutical
company focused on gastroenterology. The Company develops and
markets a broad line of prescription products to treat a range of
gastrointestinal diseases and disorders such as inflammatory bowel
disease, irritable bowel syndrome, cholestatic liver diseases and
complications related to pancreatic insufficiency. Axcan's products
are marketed by its own specialized sales forces in North America
and Europe and through commercial collaborations in many markets
around the world. Its common shares are listed on the NASDAQ Global
Market under the symbol "AXCA" and on the Toronto Stock Exchange
under the symbol "AXP".
ABOUT TPG CAPITAL
TPG Capital is the global buyout group of TPG, a leading private
investment firm founded in 1992, with more than $35 billion of
assets under management and offices in San Francisco, London, Hong
Kong, New York, Minneapolis, Fort Worth, Melbourne, Menlo Park,
Moscow, Mumbai, Beijing, Shanghai, Singapore and Tokyo. TPG Capital
has extensive experience with global public and private investments
executed through leveraged buyouts, recapitalizations, spinouts,
joint ventures and restructurings. Please visit www.tpg.com.
"Safe Harbor" statement under the Private Securities Litigation
Reform Act of 1995.
This release contains forward-looking statements, which reflect
the Company's current expectations regarding future events. To the
extent any statements made in this release contain information that
is not historical, these statements are essentially forward-looking
and are often identified by words such as "anticipate," "expect,"
"estimate," "intend," "project," "plan" and "believe."
Forward-looking statements are subject to risks and uncertainties,
including the difficulty of predicting FDA and other regulatory
approvals, acceptance and demand for new pharmaceutical products,
the impact of competitive products and pricing, new product
development and launch, reliance on key strategic alliances,
availability of raw materials, the regulatory environment,
fluctuations in operating results, the protection of our
intellectual property and other risks detailed from time to time in
the Company's filings with the Securities and Exchange and the
Canadian Securities regulators. The Company cautions that the
foregoing list of factors that may affect future results is not
exhaustive. Axcan undertakes no obligation to update or revise any
forward-looking statement, unless obligated to do so pursuant to
applicable securities laws and regulations.
The names AXCAN and AXCAN PHARMA appearing in this press release
are trademarks or registered trademarks of Axcan Pharma Inc. and
its subsidiaries.
Contacts: Axcan Pharma Inc. Isabelle Adjahi Senior Director,
Investor Relations and Communications 450-467-2600 ext. 2000
www.axcan.com
Axcan Pharma (MM) (NASDAQ:AXCA)
Historical Stock Chart
From Dec 2024 to Jan 2025
Axcan Pharma (MM) (NASDAQ:AXCA)
Historical Stock Chart
From Jan 2024 to Jan 2025
